Option chain shows key data for Cellectis's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Cellectis.

Cellectis (NASDAQ:CLLS) Stock, Option Chain

Cellectis

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

CLLS


([content-module:CompanyOverview, NASDAQ:CLLS)
Cellectis S.A. (NASDAQ:CLLS) is a clinical-stage biotechnology company focused on developing &#39;off-the-shelf&#39; cancer immunotherapies using gene-editing technology.

Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AAOI

BTOG

DGLY

DOCU

ICON

LGCB

OLMA

RBRK

RDUS

RNAZ

SEPN

SIBN

SNES

ULTA

XPEV

XPOF

Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Earnings

Penny Stocks

Upgrades

Analyst Ratings

Cellectis S.A. (NASDAQ: CLLS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.

Cellectis Upgraded to Buy: Here&#39;s Why

Cellectis S.A. - American Depositary Shares

Cellectis SA

Press Releases

Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress

Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024

Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting

Financing

Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)

Management

Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

Cellectis Presents 'Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025

Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update

Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting

CBUS

CLXT

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Alector

Editas Medicine

Fate Therapeutics

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

TuHURA Biosciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Inhibrx Biosciences

INmune Bio

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Inventiva S.A. - American Depository Shares

Inventiva

Lexeo Therapeutics

Lyell Immunopharma

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nanobiotix

Nkarta

Puma Biotechnology

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Tango Therapeutics

Tevogen Bio Holdings

Barclays

Oppenheimer

JMP Securities

Citigroup

Goldman Sachs

Comments

Cellectis

Cellectis (CLLS) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell